Orsiro Mission®DES

Arzneimitteleluierender Stent mit hervorragenden Patientenergebnissen

Finde mehr heraus
Orsiro Mission®DES

Orsiro®DES

Orsiro DES, Verbesserung der Patientenergebnisse, Jahr für Jahr2

Finde mehr heraus
Orsiro®DES

Clinically Proven

Magmaris’ clinical body of evidence keeps growing with new data from BIOSOLVE-IV

Find out more
Clinically Proven

Orsiro - probieren Sie es selbst

KONTAKTIERE UNS
home clinical

Clinical Study Highlights

Device (97.3%) and procedure success rate (98.9%) are both excellent

BIOSOLVE-IV: 12-month follow-up of the first cohort with 1,075 patients2

Find out more
News At a Glance

Future of Resorbable Scaffolds Looks Rosier

READ ARTICLE

TCT 2019: Real-World Registry Data Confirm Safety of Resorbable Scaffold Technology

READ ARTICLE

EuroPCR 2019: New Data Confirms Future of Resorbable Magnesium Scaffolds

READ ARTICLE
NewsRoom

1. According to the Magnesium 2,000 program; 2. Verheye S. Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First Cohort Subjects at 12-month Follow-up of the BIOSOLVE-IV Registry. Presented at: TCT; September 25, 2019; San Francisco, USA. NCT02817802; (n = 2,054; 1,075 patients presented); Target Lesion Failure (TLF) is defind as a composite of Cardiac Death, Target-Vessel Myocardial Infarction (TV-MI), Clinically-Driven Target Lesion Revascularization (CD-TLR) and emergent CABG.


​​​​​​​Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.
​​​​​​​Magmaris is currently not available in the US.

© 2021 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.